BioCardia (BCDA) stock price is $0.98, down 5.54% on the day, as of Oct 21, 2026. It has a market cap of $11.85Mn, and is classified in the Gene and Cell Therapy industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap11.85 Mn
P/E-1.62
Div. Yield0.00
Add ratio to table…
About
BioCardia, Inc. is a regenerative medicine company focused on the development and commercialization of cellular therapies and catheter-based delivery systems for the treatment of cardiovascular diseases. The company's primary activities involve the research, development, and potential commercialization of autologous cell therapies designed to improve heart function following myocardial infarction or in patients with chronic heart failure. BioCardia operates within the…
BioCardia, Inc. is a regenerative medicine company focused on the development and commercialization of cellular therapies and catheter-based delivery systems for the treatment of cardiovascular diseases. The company's primary activities involve the research, development, and potential commercialization of autologous cell therapies designed to improve heart function following myocardial infarction or in patients with chronic heart failure. BioCardia operates within the broader biotechnology and medical device industries, specifically targeting innovations in cardiac regenerative medicine. Its work centers on leveraging stem cell technology to address unmet medical needs in heart disease treatment.
BioCardia generates revenue primarily through the development and potential licensing of its proprietary cell therapy products and associated delivery systems. The company's revenue model relies on advancing its therapeutic candidates through preclinical and clinical development stages, with the goal of securing partnerships, collaborations, or eventual product sales. Currently, BioCardia does not have any commercial products on the market and therefore does not generate revenue from product sales. Its financial support comes from research grants, licensing agreements, equity financing, and strategic partnerships aimed at advancing its pipeline candidates toward clinical proof of concept and potential regulatory approval.
The company operates through the following segments:
Cell Therapy: This segment focuses on the development of autologous mesenchymal stem cell and cardiomyocyte therapies designed to repair damaged heart tissue. The company's lead product candidate in this segment is its proprietary CardiAMP cell therapy system, which involves harvesting a patient's own bone marrow cells, processing them to concentrate therapeutic cells, and delivering them directly to the heart via a minimally invasive catheter-based approach. The CardiAMP therapy is being evaluated in clinical trials for patients with ischemic heart failure following myocardial infarction.
Catheter Delivery Systems: This segment encompasses the development and optimization of specialized catheter devices used to deliver therapeutic agents, including cells, to specific regions of the heart. BioCardia's proprietary catheter systems are engineered to enable precise, minimally invasive intramyocardial delivery of cells or biologics while minimizing procedural risks. These delivery systems are designed to work in conjunction with its cell therapy candidates but may also have broader applications in the delivery of other therapeutic agents. The company's catheter technology includes features such as real-time imaging compatibility and adjustable infusion controls to enhance procedural accuracy and safety.
BioCardia occupies a specialized niche within the competitive landscape of regenerative medicine and cardiovascular device companies. It faces competition from other firms developing cell-based therapies for heart failure, including major pharmaceutical companies and specialized biotechnology firms pursuing allogeneic or autologous cell approaches. The company's competitive advantages lie in its proprietary catheter-based delivery platform, which addresses a critical challenge in cell therapy—achieving targeted and sustained retention of therapeutic cells in the myocardium. Its focus on autologous cell processing and point-of-care delivery differentiates it from competitors relying on off-the-shelf allogeneic products, potentially reducing immunological risks and manufacturing complexity.
BioCardia's customer base consists primarily of hospitals, clinical research institutions, and cardiology centers that participate in its clinical trials or may eventually adopt its therapies upon regulatory approval. The company engages with interventional cardiologists, cardiac surgeons, and specialized treatment centers experienced in advanced catheter-based procedures and heart failure management. While specific customer names are not disclosed in the filing, the company's commercialization strategy will depend on establishing relationships with high-volume cardiac care facilities capable of performing its minimally invasive delivery procedures.
Sector:HealthcareSector rationaleBioCardia is a regenerative medicine company developing autologous cell therapies (Biotechnology) and catheter-based delivery systems (Medical Devices) for cardiovascular diseases. Its revenue model is based on the development, licensing, and potential sale of these medical products to hospitals and cardiology centers, which falls squarely within the Healthcare sector.Industries:Gene and Cell TherapyGene and Cell TherapyPrimaryBioCardia is a regenerative medicine company focused on developing autologous mesenchymal stem cell and cardiomyocyte therapies, specifically its CardiAMP cell therapy system. Its core business is the modification and delivery of cells to repair damaged heart tissue, which fits the definition of cell therapy.Medical DevicesMedical DevicesSecondaryThe company develops and optimizes specialized catheter-based delivery systems designed for precise, minimally invasive intramyocardial delivery of cells or biologics. These are therapeutic medical devices engineered to enhance procedural accuracy and safety.Classified using BQ-MICSCIK: 0000925741
Bull & bear
Investment Thesis
▲ Bull case
BioCardia is positioned to capture significant value from its CardiAMP Cell Therapy in Japan, where management estimates an initial addressable market of 20,000 patients with ischemic heart failure, leveraging the $20,000 U.S. reimbursement rate to project a $400 million market opportunity. This projection is particularly compelling because Japan previously reimbursed a competing cardiac cell therapy at approximately $124,000 per procedure, indicating a historical willingness to pay premium prices for innovative cardiac regenerative treatments. Despite CardiAMP’s lower price point, its cost-effectiveness, combined with strong clinical data showing reduced left ventricular remodeling and statistically significant composite outcomes in biomarker-elevated patients, positions it for rapid adoption within Japan’s guideline-directed medical therapy framework. The PMDA’s expressed inclination to accept the trial data as the basis for approval, coupled with the planned 19-month timeline to commercialization (including 7 months for Shonin application preparation and a 1-year review), creates a near-term catalyst that is not fully reflected in the current valuation. Furthermore, the requirement for a reimbursed post-marketing study involving Japan’s leading cardiology societies transforms what could be a regulatory hurdle into a commercial accelerator, enabling real-world evidence generation while generating early revenue and establishing standard-of-care benchmarks. This structured post-approval pathway reduces commercialization risk and enhances long-term adoption potential, especially as BioCardia’s existing Morph platform — with roughly 100 FDA-cleared interventional products — provides proven manufacturing and quality systems that mitigate scale-up concerns.
The ongoing CardiAMP Heart Failure II trial represents a de-risked pathway to U.S. premarket approval, with FDA explicitly confirming that PMA is the appropriate regulatory route and expressing no safety concerns. The agency’s feedback described the data as “intriguing” and encouraged trial completion to support the PMA, while also offering specific guidance on statistical endpoint nuances — a level of engagement that suggests strong regulatory alignment. With 4 activated sites already enrolling and a target of 160 patients for 80% power (out of a 250-patient design), the trial is progressing despite limited disclosure on exact enrollment numbers, and management’s commitment to onboard additional sites as resources allow indicates adaptive execution. Crucially, the trial builds on the original CardiAMP HF trial’s blinded echocardiography data — a rare, long-term, contrast-enhanced endpoint showing treated patients avoided detrimental left ventricular volume increases over time, unlike controls — which directly addresses a key pathophysiological driver of heart failure progression. This mechanistic insight, suggesting microvascular repair and reduced fibrosis, is not merely incremental but represents a novel mechanism of action that could differentiate CardiAMP in a crowded heart failure therapeutics landscape. The FDA’s willingness to engage on statistical nuances, combined with the absence of safety concerns, implies that success in HF II is not merely possible but probable, setting the stage for a U.S. PMA submission that could unlock the $20,000 per procedure Medicare reimbursement domestically — a near-term catalyst parallel to Japan’s opportunity.
The Helix Transendocardial Delivery System presents an underappreciated upside optionality that management did not emphasize during the call but which the FDA actively endorsed as having dual approval pathways. The FDA confirmed no concerns regarding Helix safety data, device performance, or compatibility, and explicitly suggested that a follow-on presubmission incorporating agency advice could enable clearance via the de novo pathway as a standalone device. This is significant because the de novo pathway is typically faster and less burdensome than PMA, especially for novel devices without predicates, and would allow Helix to be commercialized independently of CardiAMP’s therapeutic approval. While management framed Helix approval as ideally simultaneous with CardiAMP, the FDA’s suggestion of a de novo route implies that Helix could reach market earlier — potentially generating revenue to fund CardiAMP HF II and Japan submission activities — thereby reducing dilution risk and accelerating cash flow generation. Given that BioCardia already controls the manufacturing and quality systems for its interventional platforms, scaling Helix production post-approval would face minimal operational friction. This standalone device opportunity, particularly in the large market for endocardial access in structural heart procedures, represents a hidden leverage point that could transform BioCardia from a single-product bet into a multi-revenue-stream medtech company, a narrative that remains underpriced in the current market assessment.
BioCardia is positioned to capture significant value from its CardiAMP Cell Therapy in Japan, where management estimates an initial addressable market of 20,000 patients with ischemic heart failure, leveraging the $20,000 U.S. reimbursement rate to project a $400 million market opportunity. This projection is particularly compelling because Japan previously reimbursed a competing cardiac cell therapy at approximately $124,000 per procedure, indicating a historical willingness to pay premium prices for innovative cardiac regenerative treatments. Despite CardiAMP’s lower price point, its cost-effectiveness, combined with strong clinical data showing reduced left ventricular remodeling and statistically significant composite outcomes in biomarker-elevated patients, positions it for rapid adoption within Japan’s guideline-directed medical therapy framework. The PMDA’s expressed inclination to accept the trial data as the basis for approval, coupled with the planned 19-month timeline to commercialization (including 7 months for Shonin application preparation and a 1-year review), creates a near-term catalyst that is not fully reflected in the current valuation. Furthermore, the requirement for a reimbursed post-marketing study involving Japan’s leading cardiology societies transforms what could be a regulatory hurdle into a commercial accelerator, enabling real-world evidence generation while generating early revenue and establishing standard-of-care benchmarks. This structured post-approval pathway reduces commercialization risk and enhances long-term adoption potential, especially as BioCardia’s existing Morph platform — with roughly 100 FDA-cleared interventional products — provides proven manufacturing and quality systems that mitigate scale-up concerns.
The ongoing CardiAMP Heart Failure II trial represents a de-risked pathway to U.S. premarket approval, with FDA explicitly confirming that PMA is the appropriate regulatory route and expressing no safety concerns. The agency’s feedback described the data as “intriguing” and encouraged trial completion to support the PMA, while also offering specific guidance on statistical endpoint nuances — a level of engagement that suggests strong regulatory alignment. With 4 activated sites already enrolling and a target of 160 patients for 80% power (out of a 250-patient design), the trial is progressing despite limited disclosure on exact enrollment numbers, and management’s commitment to onboard additional sites as resources allow indicates adaptive execution. Crucially, the trial builds on the original CardiAMP HF trial’s blinded echocardiography data — a rare, long-term, contrast-enhanced endpoint showing treated patients avoided detrimental left ventricular volume increases over time, unlike controls — which directly addresses a key pathophysiological driver of heart failure progression. This mechanistic insight, suggesting microvascular repair and reduced fibrosis, is not merely incremental but represents a novel mechanism of action that could differentiate CardiAMP in a crowded heart failure therapeutics landscape. The FDA’s willingness to engage on statistical nuances, combined with the absence of safety concerns, implies that success in HF II is not merely possible but probable, setting the stage for a U.S. PMA submission that could unlock the $20,000 per procedure Medicare reimbursement domestically — a near-term catalyst parallel to Japan’s opportunity.
The Helix Transendocardial Delivery System presents an underappreciated upside optionality that management did not emphasize during the call but which the FDA actively endorsed as having dual approval pathways. The FDA confirmed no concerns regarding Helix safety data, device performance, or compatibility, and explicitly suggested that a follow-on presubmission incorporating agency advice could enable clearance via the de novo pathway as a standalone device. This is significant because the de novo pathway is typically faster and less burdensome than PMA, especially for novel devices without predicates, and would allow Helix to be commercialized independently of CardiAMP’s therapeutic approval. While management framed Helix approval as ideally simultaneous with CardiAMP, the FDA’s suggestion of a de novo route implies that Helix could reach market earlier — potentially generating revenue to fund CardiAMP HF II and Japan submission activities — thereby reducing dilution risk and accelerating cash flow generation. Given that BioCardia already controls the manufacturing and quality systems for its interventional platforms, scaling Helix production post-approval would face minimal operational friction. This standalone device opportunity, particularly in the large market for endocardial access in structural heart procedures, represents a hidden leverage point that could transform BioCardia from a single-product bet into a multi-revenue-stream medtech company, a narrative that remains underpriced in the current market assessment.
BioCardia’s liquidity position remains critically constrained, with only $951,000 in cash and cash equivalents at quarter-end, despite sequential expense reductions. The company’s net cash used in operations was $1.7 million for Q1 FY26 — slightly above the $1.6 million in the prior year period — indicating that burn rate remains stubbornly high relative to its cash runway. Management’s stated expectation to “complete one or more transactions” in Q2 FY26 to fund both the Japan PMDA submission and CardiAMP Heart Failure II trial underscores the immediacy of the financing need, yet provides no detail on the structure, timing, or potential dilution impact of these transactions. Given the company’s history of losses and limited revenue generation, any near-term financing is likely to take the form of equity issuance or debt with restrictive covenants, which could substantially dilute existing shareholders or impose burdensome repayment obligations. The absence of any confirmed financing commitments, coupled with the broad phrasing “one or more transactions,” introduces significant execution risk — particularly if market conditions deteriorate or investor sentiment toward early-stage biotech worsens. This financing gap is not merely a tactical hurdle but a strategic vulnerability that could delay both the Japan submission (currently targeted for ~7 months from now) and HF II trial completion, thereby pushing back the 19-month commercialization timeline for Japan and undermining the near-term catalyst narrative. Without secured funding, the risk of trial enrollment delays or regulatory submission postponements becomes material, especially as the company relies on progressive site activation for HF II, which is contingent on resource availability.
While the FDA’s feedback on CardiAMP Heart Failure II was constructive, the agency stopped short of endorsing the current data as sufficient for PMA submission, instead explicitly encouraging completion of the HF II trial to provide support — a nuance that suggests the existing CardiAMP HF trial data, despite its positive echocardiographic and composite outcome signals, may not be adequate on its own for approval. The trial’s primary reliance on a composite endpoint (survival without LVAD/transplant, fewer major cardiac events, better quality of life) introduces complexity and potential variability, particularly as the statistical significance was only demonstrated in the subgroup with elevated biomarkers — a subset that may not represent the broader ischemic heart failure population. This subgroup dependency raises concerns about generalizability and could lead to labeling restrictions that limit the addressable market. Furthermore, the FDA’s engagement on “nuances of our composite endpoint” implies lingering skepticism about the endpoint’s validity or sensitivity, which could necessitate additional data collection, larger sample sizes, or alternative endpoints in HF II — all of which would increase time, cost, and execution risk. The absence of any discussion about mortality as a primary endpoint, despite it being the gold standard in heart failure trials, further underscores the reliance on surrogate and composite measures that regulators may view with caution. If HF II fails to replicate the subgroup-driven significance or if the composite endpoint is deemed insufficiently robust, the PMA pathway could be delayed or derailed, leaving BioCardia without a near-term U.S. revenue catalyst despite its breakthrough designation.
The Japan market opportunity, while numerically compelling at $400 million based on 20,000 patients and $20,000 reimbursement, rests on several fragile assumptions that management did not adequately stress-test during the call. The estimate of 300,000 total ischemic heart failure patients in Japan is broad, but the assumption that only 20,000 will be eligible under “appropriate use conditions” implies a very narrow initial indication — potentially restricted to patients with specific biomarker profiles, ejection fraction thresholds, or comorbidities that mirror the HF II trial design. This restriction could significantly slow adoption, especially if cardiologists in Japan are hesitant to adopt a new, complex cell-based therapy without long-term real-world data, even with a reimbursed post-marketing study. Moreover, the comparison to the prior $124,000-reimbursed cardiac cell therapy is misleading without context: that therapy may have been approved under different regulatory standards, targeted a distinct patient population, or benefited from temporary reimbursement policies that are no longer applicable. There is no guarantee that Japan will maintain or replicate such high reimbursement levels for CardiAMP, particularly given its lower price point and the country’s stringent cost-containment mechanisms in its universal healthcare system. The post-marketing study, while reimbursed, introduces delay and uncertainty — as data collection and societal alignment could take years — and any negative signals from this surveillance could trigger reimbursement reviews or indication restrictions. Without clarity on the exact criteria for the initial 20,000-patient indication or real-world adoption rates in similar therapies, the $400 million figure remains speculative and highly sensitive to regulatory and clinical execution risks that are not reflected in the current valuation.
BioCardia’s liquidity position remains critically constrained, with only $951,000 in cash and cash equivalents at quarter-end, despite sequential expense reductions. The company’s net cash used in operations was $1.7 million for Q1 FY26 — slightly above the $1.6 million in the prior year period — indicating that burn rate remains stubbornly high relative to its cash runway. Management’s stated expectation to “complete one or more transactions” in Q2 FY26 to fund both the Japan PMDA submission and CardiAMP Heart Failure II trial underscores the immediacy of the financing need, yet provides no detail on the structure, timing, or potential dilution impact of these transactions. Given the company’s history of losses and limited revenue generation, any near-term financing is likely to take the form of equity issuance or debt with restrictive covenants, which could substantially dilute existing shareholders or impose burdensome repayment obligations. The absence of any confirmed financing commitments, coupled with the broad phrasing “one or more transactions,” introduces significant execution risk — particularly if market conditions deteriorate or investor sentiment toward early-stage biotech worsens. This financing gap is not merely a tactical hurdle but a strategic vulnerability that could delay both the Japan submission (currently targeted for ~7 months from now) and HF II trial completion, thereby pushing back the 19-month commercialization timeline for Japan and undermining the near-term catalyst narrative. Without secured funding, the risk of trial enrollment delays or regulatory submission postponements becomes material, especially as the company relies on progressive site activation for HF II, which is contingent on resource availability.
While the FDA’s feedback on CardiAMP Heart Failure II was constructive, the agency stopped short of endorsing the current data as sufficient for PMA submission, instead explicitly encouraging completion of the HF II trial to provide support — a nuance that suggests the existing CardiAMP HF trial data, despite its positive echocardiographic and composite outcome signals, may not be adequate on its own for approval. The trial’s primary reliance on a composite endpoint (survival without LVAD/transplant, fewer major cardiac events, better quality of life) introduces complexity and potential variability, particularly as the statistical significance was only demonstrated in the subgroup with elevated biomarkers — a subset that may not represent the broader ischemic heart failure population. This subgroup dependency raises concerns about generalizability and could lead to labeling restrictions that limit the addressable market. Furthermore, the FDA’s engagement on “nuances of our composite endpoint” implies lingering skepticism about the endpoint’s validity or sensitivity, which could necessitate additional data collection, larger sample sizes, or alternative endpoints in HF II — all of which would increase time, cost, and execution risk. The absence of any discussion about mortality as a primary endpoint, despite it being the gold standard in heart failure trials, further underscores the reliance on surrogate and composite measures that regulators may view with caution. If HF II fails to replicate the subgroup-driven significance or if the composite endpoint is deemed insufficiently robust, the PMA pathway could be delayed or derailed, leaving BioCardia without a near-term U.S. revenue catalyst despite its breakthrough designation.
The Japan market opportunity, while numerically compelling at $400 million based on 20,000 patients and $20,000 reimbursement, rests on several fragile assumptions that management did not adequately stress-test during the call. The estimate of 300,000 total ischemic heart failure patients in Japan is broad, but the assumption that only 20,000 will be eligible under “appropriate use conditions” implies a very narrow initial indication — potentially restricted to patients with specific biomarker profiles, ejection fraction thresholds, or comorbidities that mirror the HF II trial design. This restriction could significantly slow adoption, especially if cardiologists in Japan are hesitant to adopt a new, complex cell-based therapy without long-term real-world data, even with a reimbursed post-marketing study. Moreover, the comparison to the prior $124,000-reimbursed cardiac cell therapy is misleading without context: that therapy may have been approved under different regulatory standards, targeted a distinct patient population, or benefited from temporary reimbursement policies that are no longer applicable. There is no guarantee that Japan will maintain or replicate such high reimbursement levels for CardiAMP, particularly given its lower price point and the country’s stringent cost-containment mechanisms in its universal healthcare system. The post-marketing study, while reimbursed, introduces delay and uncertainty — as data collection and societal alignment could take years — and any negative signals from this surveillance could trigger reimbursement reviews or indication restrictions. Without clarity on the exact criteria for the initial 20,000-patient indication or real-world adoption rates in similar therapies, the $400 million figure remains speculative and highly sensitive to regulatory and clinical execution risks that are not reflected in the current valuation.